Understanding CJC 1295 DAC
CJC 1295 DAC 2mg is a modified growth hormone releasing hormone (GHRH) analogue peptide that incorporates Drug Affinity Complex (DAC) technology to extend its biological half-life. This synthetic peptide represents an advanced iteration of the naturally occurring GHRH(1-29) sequence, engineered with specific amino acid substitutions and the addition of DAC for prolonged stability. Researchers at Stroid UK Shop can examine this compound’s molecular interactions with GHRH receptors and investigate its potential applications in growth hormone axis modulation studies. The DAC modification distinguishes this variant from standard CJC-1295, providing researchers with an extended-release formulation for comprehensive temporal analysis.
Laboratory Applications
Laboratory studies focus on CJC 1295 DAC’s binding affinity to GHRH receptors and subsequent growth hormone secretion patterns in cellular and tissue models. Research protocols examine the compound’s pharmacokinetic profile, particularly the extended half-life conferred by DAC conjugation, which allows for less frequent dosing schedules in experimental designs. Comparative studies between DAC and non-DAC variants provide insights into peptide modification strategies for enhanced bioavailability. Investigators studying peptides utilise this compound to evaluate growth hormone axis regulation, circadian release patterns, and potential synergistic effects with other growth hormone secretagogues. Research applications extend to metabolic studies examining insulin-like growth factor-1 (IGF-1) expression and downstream signalling pathways. Scientists also investigate the compound’s stability characteristics and storage requirements for optimal research conditions. CJC 1295 peptide research encompasses cellular receptor binding studies, tissue-specific expression analysis, and comparative pharmacological profiling. Advanced research protocols examine the compound’s interaction with other members of the growth hormone releasing family and potential applications in age-related research models. Investigators studying SARMs often incorporate peptide research for comprehensive endocrine system analysis.
Technical Specifications
| Parameter | Specification |
|---|---|
| Product Name | CJC 1295 DAC 2mg |
| Manufacturer | Hubio Pharm |
| Purity | Verify with supplier |
| Molecular Weight | Verify with supplier |
| CAS Number | Verify with supplier |
| Storage Conditions | Lyophilised: -20°C, Reconstituted: 2-8°C |
| Formulation | 2mg vial, lyophilised powder |
| Solubility | Water soluble when reconstituted |
Research Compliance
This product is supplied strictly for in-vitro laboratory research purposes only. CJC 1295 DAC 2mg is not intended for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must maintain appropriate storage conditions and follow institutional guidelines for peptide handling and disposal. All studies should be conducted in accordance with relevant research protocols and safety standards.
